Low Level Light Therapy for Acne Treatment: A comparison between blue-red combination LED phototherapy and 4% benzoyl peroxide wash for mild-to-moderate acne vulgaris

Date Added
October 28th, 2026
PRO Number
Pro00148108
Researcher
Lara Wine Lee

List of Studies

Keywords
Skin
Summary

Acne affects over 50 million Americans every year, with teens and young adults making up the vast majority of cases. While standard acne medicines often work well, they can sometimes cause significant side effects like dry, peeling, or irritated skin. Because of this, researchers are looking into alternative options, such as light-based treatments, that might clear breakouts without the harsh side effects. The goal of this study is to test a new at-home treatment for mild to moderate acne to see if it is safe and effective. Specifically, we aim to determine if combining a special blue and red LED light device with a common acne face wash (benzoyl peroxide) works better than using the face wash by itself. Since this specific combination of light therapy and face wash hasn't been tested on teens yet, we hope the results will give young people a new way to clear their skin and feel more confident in their daily lives.

Institution
MUSC
Recruitment Contact
Nolan Steevens
(603)-562-5026
steevens@musc.edu

A double-blind, double-dummy, parallel group, multicenter Phase 3 extension study evaluating the long-term safety and efficacy of 2 doses of remibrutinib in adult participants with moderate to severe hidradenitis suppurativa

Date Added
October 21st, 2026
PRO Number
Pro00152173
Researcher
Lara Wine Lee

List of Studies

Keywords
Skin
Summary

This research study is designed to evaluate the long-term safety and efficacy of remibrutinib in adult patients with moderate to severe hidradenitis suppurativa (HS). Participants will receive one of two remibrutinib dosing regimens: Dose A (10 mg twice daily) or Dose B (25 mg twice daily). The study aims to determine whether long-term treatment with remibrutinib is safe, well tolerated, and effective in reducing the signs and symptoms of HS.

Institution
MUSC
Recruitment Contact
Chadrick Schwipper
843-876-3209
schwippe@musc.edu

Topical Minocycline Foam for Treatment of Confluent and Reticulated Papillomatosis (CARP)

Date Added
September 8th, 2026
PRO Number
Pro00140636
Researcher
Lara Wine Lee

List of Studies

Keywords
Drug Studies, Skin
Summary

This study will look at whether a topical medication called minocycline foam (AMZEEQ) can help treat confluent and reticulated papillomatosis (CARP), a skin condition that causes dark, scaly patches. We will also evaluate how safe the treatment is and how satisfied patients are with it. The study is open to participants ages 9 years and older.

Participants will apply minocycline foam to one side of the affected skin and a moisturizing cream (emollient) to the other side for 5 weeks. This allows us to compare the two treatments in the same person. After this period, participants may choose to continue using the minocycline foam on all affected areas.

During the study, participants will attend follow-up visits where photos of the skin will be taken and the condition of the skin will be evaluated. Participants will also complete brief surveys about how their skin condition affects their quality of life and how satisfied they are with the treatment. The research team will monitor treatment use and any side effects.

The goal of this study is to learn whether topical minocycline could be a safe and effective treatment option for CARP, potentially providing an alternative to oral antibiotics.

Institution
MUSC
Recruitment Contact
Lara Wine Lee
610-715-4746
winelee@musc.edu

An Open Label Extension, Multi-Center Study to Evaluate the Safety of SD-101 Cream in Subjects with Epidermolysis Bullosa

Date Added
September 3rd, 2026
PRO Number
Pro00152287
Researcher
Lara Wine Lee

List of Studies

Keywords
Skin
Summary

Epidermolysis Bullosa is a genetic disorder manifesting typically at birth comprising several genetic subtypes that manifest as blistering or erosion of the skin in response to little or no apparent trauma. This clinical study is being conducted for research purposes. The cream being studied has allantoin as the active ingredient and the aim of this study is to assess the long-term safety of this cream when applied to the skin of participants with Epidermolysis Bullosa. This study is an open label extension to study SD-007. The study will be conducted by the study doctor, in other words, the physician responsible for the clinical study at your child's study site. Your child's participation in the clinical study is expected to last for approximately 12 months and approximately eighty (80) children will participate in this study. There will be a total of five (5) study visits over the course of one year. Study visits 1, 3 and 5 will be in person and visits 2 and 4 will be telephone visits.

Institution
MUSC
Recruitment Contact
Kennedy McLeod
843-792-4091
mcleodke@musc.edu

A Phase 3, Multi-center, Randomized, Double-Blind, Placebo Controlled Study of the Efficacy and Safety of SD-101 Cream in Patients with Epidermolysis Bullosa

Date Added
July 10th, 2026
PRO Number
Pro00150747
Researcher
Lara Wine Lee

List of Studies

Keywords
Skin
Summary

This study will compare the efficacy and safety of SD-101-6.0 cream with SD-101-0.0 (placebo) in approximately 80 patients with Epidermolysis Bullosa (EB), including Simplex, Recessive Dystrophic, and JEB-nH subtypes. Patients will apply SD-101-6.0 or placebo topically once daily to the entire body for 60 days. Each patient will have one target wound that is 21 days or older and 10–50 cm² in size selected at baseline. The primary goal is to determine how many patients in each treatment group achieve complete closure of the target wound (skin re-epithelialization without drainage) by Month 1.

Patients will return for follow-up visits around Days 14, 30, and 60 to assess wound healing using the ARANZ SilhouetteStar™ device, with the target wound measured at each visit until it is documented as closed. Secondary assessments include changes in total wound burden based on body surface area (BSA), itching, and incidence of skin infections across the entire body. Itching will be evaluated at multiple time points but will not be recorded as an adverse event. Patients who complete this trial may be eligible to enroll in an open-label extension study (SD-008) to receive active treatment. Safety will be monitored through adverse event reporting, tolerability assessments, and physical examinations, with urine pregnancy testing performed at the investigator's discretion.

Institution
MUSC
Recruitment Contact
Kennedy McLeod
843-792-4091
mcleodke@musc.edu

A phase 3, randomized, parallel, multicenter, double-blind, placebo-controlled study to investigate efficacy and safety of KP-001 in patients aged ≥2 years with common venousmalformations, common lymphatic malformations, or KTS/CLOVES syndrome

Date Added
May 5th, 2026
PRO Number
Pro00149432
Researcher
Lara Wine Lee

List of Studies

Keywords
Skin
Summary

The purpose of this study is to measure the efficacy and safety of KP-001 compared to placebo in patients with common venous malformations (VM), common lymphatic malformations (LM), or KTS/CLOVES syndrome. This phase 3, double-blind, randomized, placebo-controlled, parallel-group study will take place at multiple sites across North America. Vascular malformations like VM, LM, and KTS/CLOVES syndrome are serious, rare diseases with significant unmet medical needs. The study includes a 24-week double-blind treatment period with either KP-001 or placebo, followed by an open-label phase where all patients receive KP-001 up to Week 52. Patients weighing 40 kg or more will receive 100 mg of KP-001 once daily after breakfast, while those weighing less than 40 kg will receive a reduced dose based on their body weight.

Institution
MUSC
Recruitment Contact
Kennedy McLeod
843-792-4091
mcleodke@musc.edu

A Phase 3, Multicenter, Long-Term, Open Label Study Evaluating the Safety and Efficacy of Abrocitinib, With or Without Topical Medications Administered to Pediatric Participants Aged 2 Years and Older With Moderate-to-Severe Atopic Dermatitis

Date Added
April 16th, 2026
PRO Number
Pro00146912
Researcher
Lara Wine Lee

List of Studies

Keywords
Skin
Summary

This is an open-label, long-term study assessing the safety and efficacy of abrocitinib in participants aged 2 years and older with moderate-to-severe AD. It includes an extension cohort and a de novo cohort to meet regulatory requirements for a minimum of 300 participants exposed to 52 weeks of abrocitinib. Extension cohort participants must have completed 16 weeks of treatment in parent studies B7451023 or B7451030 and remain eligible. De novo cohort participants must be aged 6 to under 12 years at enrollment and not have participated in previous abrocitinib studies. Enrollment for the de novo cohort will begin after enrollment in Study B7451023 is complete. The study will have two periods lasting up to 2 years or until commercial availability, whichever comes first. All participants will receive abrocitinib oral suspension.

Institution
MUSC
Recruitment Contact
Andie Hoskins
843-792-6882
hoskinsa@musc.edu

A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Zasocitinib in Pediatric Participants Aged 4 to Less Than 18 Years With Moderate-to-Severe Plaque Psoriasis

Date Added
April 9th, 2026
PRO Number
Pro00149264
Researcher
Lara Wine Lee

List of Studies

Keywords
Skin
Summary

Zasocitinib (TAK-279) is an oral TYK2 inhibitor being studied as a potential treatment for moderate-to-severe plaque psoriasis in children and adolescents, a group with limited safe and effective oral options. TYK2 plays a crucial role in immune pathways involved in psoriasis, especially through IL-23's activation of Th17 cells and production of proinflammatory cytokines. Current treatments include injectable biologics and the oral agent apremilast, but few oral therapies match the efficacy of biologics. In phase 2b trials, zasocitinib showed promising results, with over two-thirds of adult participants achieving PASI-75 at certain doses by week 12 and no major safety concerns. Ongoing phase 3 trials are evaluating zasocitinib as a potential new oral treatment for pediatric plaque psoriasis.

Institution
MUSC
Recruitment Contact
Chadrick Schwipper
843-876-3209
schwippe@musc.edu

A long-term non-interventional study to assess the incidence of skin malignancies in patients with dystrophic and junctional epidermolysis bullosa receiving treatment with Filsuvez (FOSTER)

Date Added
March 26th, 2026
PRO Number
Pro00149282
Researcher
Lara Wine Lee

List of Studies

Keywords
Skin
Summary

This observational, multi-country cohort study examines the long-term safety of Filsuvez in real-world clinical practice. Researchers will collect both primary data and use existing patient registry data to gather information on Filsuvez exposure, skin malignancies, medical history, and other clinical characteristics. The study will include patients with confirmed diagnoses of DEB and JEB, regardless of whether they use Filsuvez, as long as they meet the approved indication. Patients previously exposed to Filsuvez through clinical trials, early access programs, or compassionate use programs may also participate. The study does not require any protocol-mandated visits or procedures, and the frequency of patient visits will follow local standard practice and individual patient needs.

Institution
MUSC
Recruitment Contact
Emma Edwards
8438769302
edwaremm@musc.edu

A LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF APG777 IN PATIENTS WITH ATOPIC DERMATITIS PREVIOUSLY TREATED WITH APG777

Date Added
March 4th, 2026
PRO Number
Pro00149283
Researcher
Lara Wine Lee

List of Studies

Keywords
Skin
Summary

This research study will evaluate the long-term safety and effectiveness of APG777 in patients with moderate-to-severe atopic dermatitis (AD) who have already completed treatment in a previous APG777 study. The study is multicenter and double-blind, and participants will continue with the same dose and injection schedule as in their prior study. The study includes three periods: a screening visit, an extended treatment period of about 92 weeks, and a post-treatment follow-up of up to 52 weeks. Patients who met certain improvement criteria in the previous study will continue their maintenance regimen, while others will enter an open-label Escape Arm with a different dosing schedule. The study aims to determine whether long-term use of APG777 is safe and effective for patients who may benefit from continued treatment.

Institution
MUSC
Recruitment Contact
Madeline Richmond
843-792-1436
richmoma@musc.edu



-- OR --